iiinova — where your digital self keeps evolving

Reposted by Josep Sabaté, M.D.

Guilherme Nader Marta @guinadermarta.bsky.social · 13/12/2024

Post-hoc TAILORx analysis: In HR+/HER2-, LN- breast cancer w/ RS ≥31, anthracycline (T-AC) improved 5-year DRFI (96% vs 91%, aHR 0.32, p=0.009) and DRFS vs TC. Benefit strongest in tumors >2cm, increasing with RS Results are alligned w/ other MammaPrint High 2 results @oncoalert.bsky.social

0106 10

Reposted by Josep Sabaté, M.D.

Susan Dent MD FRCPC @susandent.bsky.social · 13/12/2024

Anthracyclines still have a role in the treatment of those patients with early breast cancer at very high risk of disease recurrence!

063 6

Reposted by Josep Sabaté, M.D.

Tatiana Prowell, MD @tmprowell.bsky.social · 12/12/2024

#SABCS24 #bcsm #OncSky 🧵 COMET study randomized 957 F age 40+ w/ low risk ER+ #DCIS to guideline-concordant care (GCC, immed surgery etc) or active monitoring (AM, serial imaging-> bx/surg etc). At 2y, AM non-inferior to GCC for invasive #breastcancer, BUT important details… @oncoalert.bsky.social

1187 18

Reposted by Josep Sabaté, M.D.

Kelly Shanahan @stage4kelly.bsky.social · 13/12/2024

AWESOME slide by Dr Michael Danso summing up his approach to HR+ MBC!! #SABCS24

196 9

Reposted by Josep Sabaté, M.D.

Lorenzo Gerratana @gerratana.bsky.social · 20/12/2024

CDK4/6 inhibitors: mechanisms of resistance and where to find them. An outside of the box review Main takeaways: 🛑RB1 loss in #ctDNA predicts poorer PFS ⚠️CCNE1 gain impacts PALOMA-3 outcomes 🧩Role of ESR1 still unclear Read more👇 www.sciencedirect.com/science/arti... #bcsm #BreastCancer

sciencedirect.com

Cyclin-dependent kinase 4 and 6 inhibitors (CDK4/6i): mechanisms of resistance and where to find them

CDK4/6 inhibitors (CDK4/6i) have significantly impacted on the treatment of HR+ HER2 negative (HER2-) metastatic breast cancer (BC) when combined with…

0102 10

Reposted by Josep Sabaté, M.D.

Erika Hamilton MD, FASCO @erikahamilton9.bsky.social · 13/12/2024

Dr. Bianchini describes the 🐘 in the room at #SABCS24. ❓Are PD-L1 and PD1 not created equal in breast? 🔑It is clear, neoadjuvant compared to adj immunotherapy should be given ⚠️ highlights ER low should be included in ICI trials #SABCS24 @sabcs.bsky.social @oncoalert.bsky.social

0189 18

Reposted by Josep Sabaté, M.D.

Julia Maués @itsnotpink.bsky.social · 13/12/2024

No standing ovations at #SABCS24, but maybe there should have been! 🎤 (Granted, I didn’t catch everything in the room.) For MBC, the #PATINA and #EMBER data bring meaningful progress for patients with ER+ & triple-positive breast cancer. Exciting strides being made.

2288 28

Reposted by Josep Sabaté, M.D.

Dana-Farber’s Breast Oncology Center @dfcibreastonc.bsky.social · 17/12/2024

Check out this new systematic review and meta-analysis discussing #AntibodyDrugConjugates in patients with advanced/metastatic HER2-low-expressing #BreastCancer. 🔓https://pubmed.ncbi.nlm.nih.gov/39574495/ @ptarantinomd.bsky.social

1103 10

Reposted by Josep Sabaté, M.D.

Sarah Sammons MD @drsarahsammons.bsky.social · 11/12/2024

RLY2608 is a mutant specific PIK3CA inhibitor sparing Wildtype Receptor. 2nd line PFS >11 months with fulvestrant. Improved safety profile with low grade hyperglycemia, no rash, diarrhea, or oral sores. Hoping this one moves forward! #SABCS24 @oncoalert.bsky.social @oncbrothers.bsky.social

22211 22

Reposted by Josep Sabaté, M.D.

Ilana Schlam @ilanaschlam.bsky.social · 17/11/2024

Updated treatment algorithms for breast cancer now include adjuvant ribociclib and inavolisib, along with key trial names. Thrilled to see we're truly running out of space in HR+ disease—progress is here, with much more to come for all breast cancer subtypes!

37216 72